Enzymotec (Enzymotec) Interest Expense : $0.00 Mil (TTM As of Sep. 2017)

View and export this data going back to 2013. Start your Free Trial

What is Enzymotec Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Enzymotec's interest expense for the three months ended in Sep. 2017 was $ 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Sep. 2017 was $0.00 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Enzymotec's Operating Income for the three months ended in Sep. 2017 was $ 0.16 Mil. Enzymotec's Interest Expense for the three months ended in Sep. 2017 was $ 0.00 Mil. Enzymotec has no long-term debt ⁽¹⁾. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

Enzymotec Interest Expense Historical Data

The historical data trend for Enzymotec's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enzymotec Interest Expense Chart

Enzymotec Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Interest Expense

Get a 7-Day Free Trial

-0.66

-0.60

-0.14

-0.15

-0.17

Enzymotec Quarterly Data
	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17
Interest Expense	Get a 7-Day Free Trial															-	-	-	-	-

Enzymotec Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Sep. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Enzymotec (NAS:ENZY) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Enzymotec's Interest Expense for the three months ended in Sep. 2017 was $0.00 Mil. Its Operating Income for the three months ended in Sep. 2017 was $0.16 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Sep. 2017 was $0.00 Mil.

Enzymotec's Interest Coverage for the quarter that ended in Sep. 2017 is calculated as

Enzymotec had no long-term debt ⁽¹⁾.

The higher the ratio, the stronger the company's financial strength is.

Enzymotec (Enzymotec) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Enzymotec Ltd (NAS:ENZY) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.enzymotec.com

Enzymotec Ltd is nutritional and food ingredients company. It develops and manufactures nutritional ingredients and medical foods based on proprietary technologies. Its product portfolio includes Infat, K-Real, Enzy PS solutions, Vayacog, Vayarin and Vayaroll. The company has Nutrition and Vaya Pharma reportable segments. It derives majority of its revenues from Nutrition segment. The firm mainly operates in America, Europe, Australia, Asia, and Israel.

Enzymotec (Enzymotec) Headlines

From GuruFocus

Julian Robertson Adds to Multiple Positions in 3rd quarter

By Tiziano Frateschi Tiziano Frateschi • 12-20-2016

Julian Robertson Cuts Half of Stake in Paulson-Backed Company

By Holly LaFon Holly LaFon • 07-01-2016

Tiger Management Founder Julian Robertson Ups Stake in Enzymotec

By Kyle Ferguson Kyle Ferguson • 12-07-2015